1. Home
  2. Directory
  3. South Dakota
  4. Huron
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1760680508

MEGAN BETH NELSON-HARTMAN O.D
Prescription History 1760680508
Optometrist in Huron, SD

NPI Status: Active since July 03, 2007

Contact Information

1288 DAKOTA AVE S STE 3
HURON, SD
ZIP 57350
Phone: (605) 352-4181
Fax: (605) 352-4189

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MEGAN BETH NELSON-HARTMAN O.D, an active Optometrist specialist practicing in Huron, SD. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 379 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 203 claims alone.

Medication Index

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 11
30-Day Fills 23.7
Days Supply 700
SD State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills62.8
Peer Average Days Supply1,796
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.1% less volume than the regional standard for practitioners inside SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $245.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.32

State Avg Cost Per Claim

$28.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 16
30-Day Fills 26.1
Days Supply 785
SD State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills69.5
Peer Average Days Supply2,071
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.0% less volume than the regional standard for practitioners inside SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $277.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.31

State Avg Cost Per Claim

$24.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 70
30-Day Fills 108.3
Days Supply 3,237
SD State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills110.9
Peer Average Days Supply3,311
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,368.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.55

State Avg Cost Per Claim

$26.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 203
30-Day Fills 365.3
Days Supply 10,597
SD State Average Benchmarks
Peer Average Claims93.0
Peer Average 30-Day Fills145.0
Peer Average Days Supply4,022
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 118.3% higher than the standard regional baseline profile for SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,913.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.35

State Avg Cost Per Claim

$15.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Optometry
Provider Metrics Summary
Total Claims 24
30-Day Fills 28.5
Days Supply 724
SD State Average Benchmarks
Peer Average Claims96.0
Peer Average 30-Day Fills119.1
Peer Average Days Supply2,973
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.0% less volume than the regional standard for practitioners inside SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,207.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$91.99

State Avg Cost Per Claim

$53.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 43
30-Day Fills 76.8
Days Supply 2,244
SD State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills87.6
Peer Average Days Supply2,563
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,864.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.37

State Avg Cost Per Claim

$18.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Xiidra

Generic Formulation: LifitegrastSpecialty: Optometry
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
SD State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply739
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside SD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,722.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$726.85

State Avg Cost Per Claim

$903.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MEGAN BETH NELSON-HARTMAN O.D provides transparency into local medical care patterns within Huron, SD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.